PUBLISHER: Polaris Market Research | PRODUCT CODE: 1424093
PUBLISHER: Polaris Market Research | PRODUCT CODE: 1424093
The global oxycodone drugs market size is expected to reach USD 8.29 billion by 2032, according to a new study by Polaris Market Research. The report "Oxycodone Drugs Market Share, Size, Trends, Industry Analysis Report, By Drug Type (Short-acting, Long-acting); By Dosage Form; By Distribution Channel; By Region; Segment Forecast, 2024- 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.
Rising incidence of chronic pain disease such as cancer, rheumatoid arthritis, lower back pain, and fibromyalgia is the primary contributor for the oxycodone market expansion. Moreover, the unresponsiveness shown by other medications for the treatment of severe pain management has increased the demand for oxycodone drugs. Furthermore, promising results of these drugs and benefits associated with the extended release oxycodone drugs has increased its prescription volumes. Additionally, better compliance and convenience of less-frequent dosage intervals offered by oxycodone drugs will fuel the market growth in the coming years.
The advent of extended-release capsules coupled with the high prevalence of severe pain among adults are also propelling the market growth. Moreover, the patents owned by market players coupled with their increasing expenses on marketing and promotion will contribute to the market growth. For instance, Collegium Pharmaceutical's Xtampza ER has patent protection until 2036.
The promising results shown by the oxycodone drugs over other opioid medications is also driving the market growth. Moreover, the advent of new drugs with advancements in drug delivery systems such as extended-release formulations will provide long-term opportunity for the oxycodone drugs market growth. The ability of oxycodone to lower the severe pain after surgery coupled with an increasing number of surgical procedures are expected to support the market expansion.
The widespread acceptance of oxycodone drugs as a pain-relieving medication and growing need for oxycodone for the pain management after surgeries are the factors propelling the market growth. Moreover, the strong focus of companies on the regulatory approvals in untapped markets will positively influence the market growth. Furthermore, lack of physical activities, tobacco usage, and obesity are increasing the number of patients suffering from chronic pain. For instance, according to the World Obesity Atlas 2023 Report by the World Obesity Federation, the number of people with overweight or obesity worldwide is expected to increase to 4.0 billion, from 2.6 billion in 2020. Such obese people requiring pain management medications will drive the market growth during the forecast period.
The long-acting segment dominated the market, owing to its benefits for improving pain management and reducing pain intensity variations.
The capsules segment is expected to expand at the highest CAGR, owing to the emergence of extended release capsules.
Hospital segment held the largest market share, owing to the increasing number of surgical procedures and rising hospital admissions.
North America dominated the market, owing to the large volume of oxycodone prescriptions and rising incidences of chronic pain diseases.
The market players include Collegium Pharmaceutical, Mundipharma International, Sun Pharmaceutical Industries Ltd., Endo International plc, and Mallinckrodt.
Polaris Market Research has segmented the oxycodone drugs market report based on drug type, dosage form, distribution channel, and region: